兰德-新的治疗模式及其对NHS的变革潜力-对健康十年计划的见解（英）

Novel treatment paradigms and their transformative potential for the NHSInsights for the ten-year plan for healthSonja Marjanovic, Agnė Ulytė, Hampton Toole, Zuzanna Marciniak-Nuqui, Stephanie Stockwell, Avery Adams, Manon Richard-Sheridan, Sorana Busceneanu, Sarah Parkinson and Nick FahyTECHNICAL REPORTAcknowledgements First, we would like to thank Wellcome, our institutional delivery partner for the Future State Programme, for all of their collaboration, and especially Beth Thompson, Tom Harrison and Megan Challis for all their support and insights. We also thank all experts who informed the insights we share in this report: Naomi Allen, Jacqueline Barry, Giuseppe Battaglia, Sarah Blagden, Dennis Chan, Tim Constandinou, Gerard Cummins, Matthew Durdy, Ellen Fallows, Paul Freemont, Phillipa Hemmings, Chris Malloy, Ferdinando Rodriguez y Baena, David Veale, and Fiona Watt. We appreciate the helpful industry contributions from Valtteri Tulkki, Simon Taylor and Anita Kidgell from GSK to insights that we share in a related discussion paper. We are also grateful to experts who contributed through interviews on the current impact and future potential of novel treatment paradigms. From RAND Europe, we thank Tom Ling and Susan Guthrie for their quality assurance and Sana Zakaria for her advice. Thanks also to Amish Acharya, Georgia Butterworth, Peter Howitt and Lord Ara Darzi for helping facilitate this discussion paper.For more information on this publication, visit www.rand.org/t/RRA3842-2About RAND Europe RAND Europe is a not-for-profit research organisation that helps improve policy and decision making through research and analysis. To learn more about RAND Europe, visit www.randeurope.org.Research Integrity Our mission to help improve policy and decision making through research and analysis is enabled through our core values of quality and objectivity and our unwavering commitment to the highest level of integrity and ethical behaviour. To help ensure our research and analysis are rigorous, objective, and nonpartisan, we subject our research publications to a robust and exacting quality-assurance process; avoid both the appearance and reality of financial and other conflicts of interest through staff training, project screening, and a policy of mandatory disclosure; and pursue transparency in our research engagements through our commitment to the open publication of our research findings and recommendations, disclosure of the source of funding of published research, and policies to ensure intellectual independence. For more information, visit www.rand.org/about/research-integrity.Published by the RAND Corporation, Santa Monica, Calif., and Cambridge, UK© 2025 RAND CorporationR® is a registered trademark.Cover: Adobe StockLimited Print and Electronic Distribution Rights This publication and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorised postin